Financial Performance - The company achieved operating revenue of CNY 1,023.18 million during the reporting period, with a net loss attributable to shareholders of CNY 518.99 million[4]. - The net loss attributable to shareholders, excluding non-recurring gains and losses, was CNY 395.68 million[4]. - The company's revenue for 2022 reached approximately ¥1.02 billion, representing a 661.33% increase compared to ¥134.39 million in 2021[23]. - The net loss attributable to shareholders decreased to approximately ¥519.00 million in 2022 from ¥866.85 million in 2021[23]. - The net cash flow from operating activities improved to approximately -¥427.91 million in 2022, compared to -¥862.82 million in 2021[24]. - The total assets increased by 99.24% to approximately ¥2.74 billion at the end of 2022, up from ¥1.37 billion at the end of 2021[24]. - The company reported a basic earnings per share of -¥1.19 for 2022, an improvement from -¥1.99 in 2021[25]. - The company reported a net cash outflow from operating activities of CNY -427,909,674.49, an improvement from the previous year's outflow[126]. - The company achieved total revenue of CNY 1,023,176,678.65, representing a year-on-year growth of 661.33%[124]. - The net loss attributable to the parent company was CNY 51,899,580, a reduction of 40.13% compared to the previous year[124]. Research and Development - The company reported a total R&D investment of CNY 973.45 million in 2022, focusing on preclinical research and clinical trials[3]. - The company is committed to continuous investment in clinical and preclinical research to maintain its competitive edge in the biopharmaceutical industry[3]. - The company’s R&D expenditure accounted for 95.14% of its revenue in 2022, highlighting a significant investment in innovation[25]. - The company has 20 academic papers published in important domestic and international journals, showcasing strong research capabilities in basic research and clinical applications[41]. - The company has established a comprehensive R&D and production platform for recombinant proteins, monoclonal antibodies, and innovative vaccines, enhancing its competitive edge in the biopharmaceutical industry[71]. - The company has completed preclinical development and production of 3 neutralizing antibodies and 5 recombinant protein vaccines since early 2020, demonstrating advanced R&D speed and efficiency[81]. - The company has developed advanced detection technologies and quality analysis systems for complex biopharmaceuticals, ensuring high-quality production processes[82]. - The company has established a financial management system to ensure timely and accurate reporting, complying with regulatory requirements for fundraising[187]. - The company has invested significantly in preclinical and clinical research to enhance product competitiveness, although there are inherent risks in achieving expected clinical outcomes[113]. Product Development and Pipeline - The company is actively expanding its product pipeline and increasing R&D investments as products enter critical clinical research phases[4]. - The company reported a significant focus on innovative drugs, including monoclonal antibodies and bispecific antibodies, which are expected to enhance treatment efficacy in various diseases[13]. - The company is actively engaged in the development of biosimilars, which are expected to provide cost-effective alternatives to existing biologic therapies, enhancing market competitiveness[14]. - The company is developing SCT1000, the world's first 14-valent HPV vaccine, which covers all 12 high-risk HPV types and is currently preparing for Phase III clinical trials expected to complete enrollment by the end of 2023[72]. - The company has established a comprehensive marketing organization with over 100 distributors nationwide, focusing on both direct delivery and commercial distribution channels[59]. - The company has a rich product pipeline, with 1 recombinant protein drug and 1 monoclonal antibody product approved for market, and 2 COVID-19 vaccine products included in emergency use[108]. - The company is focused on expanding its international business, adapting its strategies to different regulatory environments and market conditions to maximize economic and social benefits[118]. Market and Competitive Landscape - The company continues to face cumulative unabsorbed losses and is expected to incur further losses in the near future[4]. - The company is facing risks related to ongoing losses and the potential for delisting if it fails to achieve profitability or if accumulated losses continue to grow[108]. - The company faces intense competition in the innovative drug market, with potential competitors developing superior products that could significantly impact its market position[116]. - The biopharmaceutical industry is facing challenges from strict regulations and rapid technological advancements, necessitating continuous innovation and adaptation from companies[69]. - The company is actively managing risks related to raw material shortages and price fluctuations, ensuring stable supplier relationships to avoid disruptions in operations[117]. Strategic Initiatives and Future Outlook - The company plans to continue expanding its market presence and product offerings, focusing on innovative therapies and strategic partnerships[26]. - Future outlook includes expanding the product portfolio with new drug applications, particularly in oncology and autoimmune disease treatments, aiming for a broader market reach[14]. - The company is exploring partnerships and collaborations to accelerate market expansion and leverage complementary technologies in drug development[14]. - The company plans to increase investment in the research and development of biopharmaceuticals and vaccines over the next decade, aiming for international market entry[181]. - The company is committed to enhancing its information technology infrastructure to improve operational efficiency and internal control[189]. Governance and Management - The company’s governance structure complies with relevant laws and regulations, ensuring that all shareholders, especially minority shareholders, can exercise their voting rights effectively[191]. - The company’s board of directors actively participates in meetings and committees, ensuring informed decision-making and protection of shareholder interests[192]. - The company has a diverse management team with a mix of genders and ages, promoting inclusivity in its leadership[196]. - The company is committed to long-term growth and stability, as indicated by the retention of key management personnel and their ongoing development[195].

Financial Performance - The company's operating revenue for Q1 2023 was ¥328,779,509.01, representing a significant increase of 111.02% compared to the same period last year[4]. - The net profit attributable to shareholders of the listed company was a loss of ¥153,011,423.00, with a net profit excluding non-recurring gains and losses of a loss of ¥58,524,478.28[4]. - The company's net loss for Q1 2023 was ¥153,769,208.59, compared to a net loss of ¥118,198,000.00 in Q1 2022, representing a worsening of 30.1%[19]. - The net profit for Q1 2023 was -153,348,003.27 CNY, compared to -143,622,878.13 CNY in Q1 2022, indicating a year-over-year increase in losses of approximately 7.5%[21]. - The company reported a total comprehensive income of -153,348,003.27 CNY for Q1 2023, compared to -143,622,878.13 CNY in Q1 2022, reflecting a decline in overall financial performance[21]. Cash Flow - The net cash flow from operating activities was negative at ¥121,991,794.43[4]. - Cash flow from operating activities showed a net outflow of -121,991,794.43 CNY, worsening from -95,350,434.30 CNY in Q1 2022[23]. - The cash flow from investing activities resulted in a net outflow of -517,667,554.98 CNY, compared to -387,170,845.31 CNY in the previous year[24]. - The net cash flow from financing activities was -51,177,831.75 RMB, compared to 351,747,155.74 RMB in the previous year, indicating a substantial decline[32]. - The company reported a total cash outflow from operating activities of 11,025,610.45 RMB, compared to 10,068,905.02 RMB in the same quarter last year, an increase of approximately 9.5%[31]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,877,949,104.54, reflecting a 5.19% increase from the end of the previous year[5]. - Total liabilities rose to ¥3,266,245,838.84 in Q1 2023, up from ¥2,978,066,553.77 in Q1 2022, marking an increase of 9.7%[17]. - The total equity attributable to shareholders decreased to -¥382,420,147.87 as of March 31, 2023, from -¥236,650,939.28 at the end of 2022, indicating a decline of 61.6%[18]. - The company's total assets decreased to CNY 3,196,335,084.75 as of March 31, 2023, down from CNY 3,254,225,625.01 at the end of 2022, reflecting a decline of 1.77%[28]. - The total owner's equity decreased to CNY 2,571,237,580.62 as of March 31, 2023, down from CNY 2,582,956,396.48 at the end of 2022, a decline of 0.43%[28]. Research and Development - Research and development expenses totaled ¥270,002,471.74, which is an increase of 43.20% year-on-year[4]. - The ratio of R&D expenses to operating revenue was 82.12%, a decrease of 38.89 percentage points compared to the previous year[5]. - R&D expenses in Q1 2023 amounted to ¥248,165,462.86, compared to ¥184,747,212.74 in Q1 2022, indicating a rise of 34.3%[19]. - Research and development expenses decreased to CNY 1,405,310.16 in Q1 2023, down 49.5% from CNY 2,781,699.28 in Q1 2022[29]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,145[10]. - The company reported a basic and diluted earnings per share of -0.34 CNY for Q1 2023, slightly worse than -0.33 CNY in Q1 2022[22]. Government Support - The company received government subsidies amounting to ¥5,849,022.36 during the quarter[6]. Inventory and Borrowings - The company's inventory increased to ¥208,846,931.26 as of March 31, 2023, from ¥191,883,056.14 at the end of 2022, an increase of 8.9%[16]. - Short-term borrowings increased to ¥599,346,189.30 in Q1 2023, compared to ¥508,449,216.36 in Q1 2022, reflecting an increase of 17.9%[17].

证券代码：688520 证券简称：神州细胞 公告编号：2023-016 北京神州细胞生物技术集团股份公司 关于召开 2022 年度暨 2023 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京神州细胞生物技术集团股份公司（以下简称"公司"）已于 2023 年 4 月 26 日在上海证券交易所网站（www.sse.com.cn）披露了公司 2022 年年度报告 及 2023 年第一季度报告。为便于广大投资者更全面深入地了解公司 2022 年度及 2023 年第一季度经营成果、财务状况，公司计划于 2023 年 5 月 9 日上午 10:00-11:00 举行 2022 年度暨 2023 年第一季度业绩说明会，就投资者关心的问题 进行交流。 一、说明会类型 本次业绩说明会以视频结合网络互动形式召开，公司将针对 2022 年度及 2023 年第一季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟 通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、方式、地点 ...

Group 1: Company Overview and R&D Investment - The company has established a high-efficiency, high-throughput technology platform covering the entire chain of biopharmaceutical R&D and production, with a focus on independent development [2] - In 2021, the company's R&D expenses reached CNY 733 million, with Q1 2022 expenses at CNY 189 million, a year-on-year increase of 21.46% [2] - The company has multiple products in various stages of clinical trials, with the first product, recombinant factor VIII (Anjain®), approved for market in July 2021 [2][3] Group 2: Market Potential and Product Pipeline - The domestic market for recombinant factor VIII is estimated at CNY 2 billion, with an annual growth rate of approximately 30% [3] - By 2023 and 2030, the number of hemophilia patients in China is expected to reach 144,000 and 146,000, respectively, indicating a growing demand for treatment [3] - The company has a pipeline that includes monoclonal antibodies and vaccines, with plans to gradually push these products into clinical stages [3][4] Group 3: Sales Performance and Market Strategy - Sales revenue for Anjain® exceeded CNY 124 million in Q4 2021 and approached CNY 156 million in Q1 2022, reflecting a quarter-on-quarter growth of 25.8% [4] - The company has established a comprehensive marketing network and a patient-centered service model to improve drug accessibility [4] - The marketing team consists of over 200 members with extensive experience in the pharmaceutical industry, focusing on improving patient health outcomes [4] Group 4: International Expansion and Future Plans - The company has initiated international cooperation for SCT800, targeting markets in India, Turkey, Indonesia, and several other countries [4] - Plans are in place to start clinical research for the 14-valent HPV vaccine (SCT1000) by the end of the year, pending successful progress in earlier trials [5] - The company aims to leverage its technology and cost advantages to expand its product offerings and enhance market competitiveness [7]

2021 年年度报告 公司代码：688520 公司简称：神州细胞 北京神州细胞生物技术集团股份公司 2021 年年度报告 1 / 223 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司上市时未盈利且尚未实现盈利 √是 □否 公司为采用第五套上市标准上市的生物医药行业公司，上市时公司尚未盈利。公司 2021 年 度尚未实现盈利且存在累计未弥补亏损。新药行业研发周期长、研发投入高，产品上市前通常需 要经过临床前研究、临床 I/II/III 期研究，单个产品的研发周期可能超过十年，研发投入数亿元； 对于多产品管线的公司，每年研发投入达到或者超过数十亿元。持续的研发投入是创新药企业保 持技术和竞争优势的关键因素之一。公司报告期内产生研发费用 73,266.21 万元，研发投入用于产 品管线的临床前研究、临床试验，快速推进现有临床项目的开展和储备项目的开发等。 公司的主要业务是单克隆抗体、重组蛋白和疫苗等生物药产品的研发和产业化，目前除针对 甲型血友病的重组八因 ...